Scientists fight deadly childhood brain cancer with re-engineered immune cells
NCT ID NCT07501156
Summary
This early-phase trial is testing a new personalized cell therapy for people with aggressive brain tumors called diffuse midline glioma or DIPG. Doctors take a patient's own immune cells, engineer them in a lab to specifically target a cancer-causing mutation called H3K27M, and then infuse them back into the patient. The main goals are to see if this treatment is safe and if it can help shrink these difficult-to-treat tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA OR DIFFUSE INTRINSIC PONTINE GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.